Contract

1 US-DOCS\131055246.15 Exhibit 10.1 Employment Agreement This Employment Agreement (the “Agreement”), entered into as of June 3, 2022, is made by and between Xxxxx Xxxxx (the “Executive”), GoHealth, Inc., a Delaware corporation (“GoHealth”), and GoHealth Holdings, LLC, a Delaware limited liability company (the “Partnership” and, together with GoHealth and any of the Affiliates of GoHealth and the Partnership as may employ the Executive from time to time, and any successor(s) thereto, the “Company”). RECITALS WHEREAS, the Company desires to engage the Executive to perform services under the terms hereof; WHEREAS, the Executive desires to provide services to the Company on the terms herein provided; and WHEREAS, the Company and the Executive desire to have the Executive’s employment begin on June 6, 2022 (the “Effective Date”). AGREEMENT NOW, THEREFORE, in consideration of the foregoing, and for other good and valuable consideration, including the respective covenants and agreements set forth below, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree, effective as of the Effective Date, as follows: 1. Certain Definitions (a) “Affiliate” shall mean, with respect to any Person, any other Person directly or indirectly controlling, controlled by, or under common control with, such Person where “control” shall have the meaning given such term under Rule 405 of the Securities Act of 1933, as amended from time to time. (b) “Agreement” shall have the meaning set forth in the preamble hereto. (c) “Annual Base Salary” shall have the meaning set forth in Section 3(a).

2 (d) “Annual Bonus” shall have the meaning set forth in Section 3(b). (e) “Board” shall mean the Board of Directors of GoHealth, Inc., a Delaware corporation. (f) The Company shall have “Cause” to terminate the Executive’s employment hereunder upon: (i)(A) the willful failure or refusal of the Executive to perform material responsibilities set forth herein (including the Executive’s failure to devote time and attention to his duties hereunder or failure to regularly attend Board or office meetings); (B) the Executive’s willful failure to carry out, or comply with, in any material respect any lawful directive of the Board; (C) dishonesty by the Executive to the Board with respect to any material matter; (D) misappropriation of funds or property of the Company or any of its Affiliates by the Executive other than the occasional, customary and de minimis use of Company property for personal purposes; or (E) a breach by the Executive of this Agreement or other agreement with the Company (including, without limitation, the Restrictive Covenants Agreement); provided, in the case of each of the foregoing clauses (A)-(E), if the Board (excluding any Board member as to whom Cause is alleged to have occurred) determines reasonably and in good faith that such act can reasonably be cured, that the Company has provided 30 days’ prior written notice to the Executive of such conduct and the Executive has failed to cure such conduct within such 30 day period in the manner identified by the Board; (ii) the arrest or charging of the Executive for (A) any felony or (B) a misdemeanor involving moral turpitude, deceit, dishonesty or fraud, and which is materially detrimental to the Company and its Affiliates (including material reputational harm); or (iii) the Executive’s engagement in on-the-job conduct that consists either of gross misconduct or a material violation of the Company or any of its Affiliates’ written code of ethics or Company policies, and which is materially detrimental to the Company and its Affiliates (including material reputational harm). (g) “Change of Control” shall have the meaning set forth in the 2020 Incentive Award Plan of the Company. (h) “Code” shall mean the Internal Revenue Code of 1986, as amended. (i) “Common Stock” shall have the meaning set forth in Section 3(c). (j) “Company” shall have the meaning set forth in the preamble hereto. (k) “Date of Termination” shall mean (i) if the Executive’s employment is

3 terminated due to the Executive’s death, the date of the Executive’s death; (ii) if the Executive’s employment is terminated due to the Executive’s Disability, the date determined pursuant to Section 4(a)(ii); or (iii) if the Executive’s employment is terminated pursuant to Section 4(a)(iii)(vi) either the date indicated in the Notice of Termination or the date specified by the Company pursuant to Section 4(b), whichever is earlier. (l) “Disability” shall mean the Executive’s inability to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment that can be expected to result in death or that can be expected to last for a continuous period of not less than twelve (12) months. (m) “Effective Date” shall have the meaning set forth in the recitals hereto. (n) “Executive” shall have the meaning set forth in the preamble hereto. (o) “Extension Term” shall have the meaning set forth in Section 2(b). (p) The Executive shall have “Good Reason” to terminate the Executive’s employment hereunder after the occurrence of one or more of the following conditions without the Executive’s consent: (A) a material adverse change in the Executive’s title, reporting relationship, authority or duties and responsibilities as of the Effective Date or an elimination of the Executive’s position; or (B) a material reduction in the Executive’s Annual Base Salary or Annual Bonus opportunity, in either case not otherwise made on a substantially similar basis for senior Company executives generally. The Executive’s employment with the Company may be terminated for Good Reason only if (1) the Executive provides written notice to the Company of the occurrence of the Good Reason event (as described above) within 30 days after the Executive knows or reasonably should have known of the circumstances constituting Good Reason, (2) the Company fails to cure the circumstances constituting “Good Reason” within 30 days after such notice, and (3) the Executive resigns within 30 days after the expiration of such 30-day cure period. For the avoidance of doubt, an initial public offering of common stock of the Company or any parent (direct or indirect) or other Affiliate of the Company shall not constitute Good Reason for purposes of this Agreement. (q) “Initial Term” shall have the meaning set forth in Section 2(b). (r) “Notice of Termination” shall have the meaning set forth in Section 4(b).

4 (s) “Person” shall mean any individual, natural person, corporation (including any non-profit corporation), general partnership, limited partnership, limited liability partnership, joint venture, estate, trust, company (including any company limited by shares, limited liability company or joint stock company), incorporated or unincorporated association, governmental authority, firm, society or other enterprise, organization or other entity of any nature. (t) “Release” shall have the meaning set forth in Section 5(b). (u) “Release Expiration Date” shall have the meaning set forth in Section 21(c). (v) “Restrictive Covenant Agreement” shall have the meaning set forth in Section 6. (w) “RSU Gain” shall mean, with respect to shares of Common Stock received by the Executive in settlement of the RSUs but no longer held by the Executive as of the Date of Termination, an amount equal to the product of (i) the number of such shares of Common Stock and (ii) the Fair Market Value (as defined in the equity incentive plan under which the RSUs are granted) per share of Common Stock on the date the Executive sold or otherwise disposed of such shares of Common Stock (without reduction for any shares of Common Stock sold or surrendered in payment of taxes, etc.). (x) “Section 409A” shall mean Section 409A of the Code and the Department of Treasury regulations and other interpretive guidance issued thereunder, including without limitation any such regulations or other guidance that may be issued after the Effective Date. (y) “Severance Period” shall have the meaning set forth in Section 5(b). (z) “Term” shall have the meaning set forth in Section 2(b). 2. Employment (a) In General. Effective as of the Effective Date, the Company shall employ the Executive under this Agreement and the Executive shall remain in the employ of the Company under this Agreement, for the period set forth in Section 2(b), in the position set forth in Section 2(c), and upon the other terms and conditions herein provided. (b) Term of Employment. The initial term of employment under this Agreement (the “Initial Term”) shall be for the period beginning on the Effective Date and ending on the third anniversary thereof, unless earlier terminated as provided in Section 4. The Initial

7 achieving a Three-Year VWAP equal to or greater than $4.00 but less than $6.00, or (iv) 200% on the VWAP Vesting Date (i.e., 2,833,334 shares of Common Stock), subject to the Company achieving a Three-Year VWAP equal to or greater than $6.00, in each case subject to the Executive’s continued employment through the VWAP Vesting Date. For the avoidance of doubt, in the event the Three-Year VWAP is less than $2.00, all VWAP RSUs shall be forfeited for no consideration on the VWAP Vesting Date. (C) Termination of Employment. (1) In the event the Executive’s employment is terminated by the Executive without Good Reason after the grant of the RSUs but prior to the 12-month anniversary of the Effective Date, then (i) any shares of Common Stock received in settlement of the RSUs and held by the Executive as of the Date of Termination shall be automatically forfeited for no consideration on such date, and (ii) the Executive shall pay to the Company in cash any RSU Gain received by the Executive, with such payment to occur no later than the thirty (30) day anniversary of the Date of Termination. For the avoidance of doubt, the claw-back provisions set forth in this Section 3(c)(i)(C) are in addition to any other claw-back policy applicable to the Executive. (2) In the event the Executive’s employment is terminated by the Company without Cause or by the Executive with Good Reason, in either case within the 90-day period immediately preceding the VWAP Vesting Date, then, effective as of immediately prior to such termination of employment, the VWAP RSUs and any unvested portion of the Initial Options as of such date shall immediately vest (and become exercisable, as applicable) in full, with the number of vested VWAP RSUs determined based on actual Three-Year VWAP performance as measured on the VWAP Vesting Date. (D) Notwithstanding anything in Section 3(c)(i)(B)(2) to the contrary, in the event of a Change in Control (as defined in the Plan): (1) prior to the eighteen-month anniversary of the Effective Date, the VWAP RSUs shall vest immediately prior to such Change in Control at the greater of (x) Target Level and (y) the vesting that would occur under Section 3(c)(i)(B)(2) if the Three-Year VWAP is assumed to be the per-share purchase price of the Company in connection with such Change in Control; or (2) on or after the eighteen-month anniversary of the Effective Date, the VWAP RSUs shall vest immediately prior to such

8 Change in Control at the greater of (x) Target Level and (y) actual volumeweighted average price performance as measured over the period beginning on the date of grant of the VWAP RSUs and ending immediately prior to such Change in Control; provided, however, that, in the event the per-share purchase price of the Company in connection with such Change in Control is greater than or equal to $6.00, the VWAP RSUs shall vest immediately prior to such Change in Control at 200%. (ii) Each fiscal year during the Term, beginning with fiscal year 2023, the Executive shall receive an annual grant of additional equity awards under the Company’s 2020 Incentive Award Plan (or another equity award plan adopted by the Company) consisting of Options, Restricted Stock Units, VWAP RSUs, and/or other awards authorized for grant under the applicable plan in amounts to be determined by the Board or the Compensation Committee thereof in its sole discretion (each such aggregate annual grant, an “Annual Award” and, together with the Initial Award, the “Equity Awards”); provided, however, that (1) each Annual Award shall be made with respect to no less than 5,000,000 aggregate shares of Common Stock; provided further, that notwithstanding the minimum number of shares of Common Stock set forth in this clause (1), in no event shall the minimum requirement under this provision for any Annual Award have an aggregate grant date dollar value (as determined by the Board or the Compensation Committee thereof in its sole discretion) of more than $15,000,000; and (2) unless otherwise determined by the Board, no more than 25% of each Annual Award shall consist of time-vesting Restricted Stock Units. (iii) The Equity Awards shall be subject to the terms of the applicable plan and applicable award agreements by and between the Executive and the Company. Without limiting the foregoing, for the avoidance of doubt and in accordance with the terms of the applicable plan, the number and kind of shares subject to any equity award described in this Section 3(c) shall, in the event of any stock dividend, stock split, combination or exchange of shares, merger, consolidation or other distribution (other than normal cash dividends) of Company assets to stockholders, or any other change affecting the shares of the Company’s stock or the share price of the Company’s stock, be equitably adjusted to reflect such change. (d) Benefits. During the Term, the Executive shall be eligible to participate in employee benefit plans, programs and arrangements of the Company in accordance with their terms, as in effect from time to time, and as are generally provided by the Company to its senior executive officers (including, without limitation, the Company’s paid time off policy for its senior executive officers as in effect from time to time). (e) Business Expenses. During the Term, the Company shall reimburse the Executive for all reasonable, documented, out-of-pocket travel (including first class or equivalent accommodations) and other business expenses incurred by the Executive in the performance of the Executive’s duties to the Company in accordance with the Company’s applicable expense reimbursement policies and procedures.

12 the Company and its goodwill, the exact amount of which will be difficult or impossible to ascertain, and that the remedies at law for any such breach will be inadequate. Accordingly, the Executive agrees that, in the event of a breach of any of the covenants contained in the Restrictive Covenant Agreement, in addition to any other remedy which may be available at law or in equity, the Company will be entitled to specific performance and injunctive relief. 8. Assignment and Successors. The Company may assign its rights and obligations under this Agreement to any entity, including any successor to all or substantially all the assets of the Company, by merger or otherwise, and may assign or encumber this Agreement and its rights hereunder as security for indebtedness of the Company and its Affiliates. The Executive may not assign the Executive’s rights or obligations under this Agreement to any individual or entity. This Agreement shall be binding upon and inure to the benefit of the Company, the Executive and their respective successors, assigns, personnel and legal representatives, executors, administrators, heirs, distributees, devisees, and legatees, as applicable. 9. Governing Law; Venue. This Agreement shall be governed, construed, interpreted and enforced in accordance with the substantive laws of the State of Delaware, without giving effect to any principles of conflicts of law, whether of the State of Delaware or any other jurisdiction, and where applicable, the laws of the United States, that would result in the application of the laws of any other jurisdiction. Each of the parties hereto agrees that any legal action or proceeding with respect to this Agreement shall be brought exclusively in the Chancery Court of New Castle County, Delaware or the federal courts of the United States of America for the District of Delaware, unless the parties to any such action or dispute mutually agree to waive this provision. By execution and delivery of this Agreement, each of the parties hereto irrevocably consents to service of process out of any of the aforementioned courts in any such action or proceeding by the mailing of copies thereof by registered or certified mail, postage prepaid, or by recognized express carrier or delivery service, to the applicable party at his, her or its address referred to herein. Each of the parties hereto irrevocably waives any objection which he, she or it may now or hereafter have to the laying of venue of any of the aforementioned actions or proceedings arising out of or in connection with this Agreement, or any related agreement, certificate or instrument referred to above, brought in the courts referred to above and hereby further irrevocably waives and agrees, to the fullest extent permitted by applicable law, not to plead or claim in any such court that any such action or proceeding brought in any such court has been brought in any inconvenient forum. Nothing herein shall affect the right of any party to serve process in any other manner permitted by law. 10. Validity. The invalidity or unenforceability of any provision or provisions of this Agreement shall not affect the validity or enforceability of any other provision of this Agreement, which shall remain in full force and effect. 11. Notices. Any notice, request, claim, demand, document and other communication hereunder to any party hereto shall be effective upon receipt (or refusal of receipt) and shall be in writing and delivered personally or sent by telex, telecopy, or certified or registered mail, postage prepaid, to the following address (or at any other address as any party hereto shall have specified by notice in writing to the other party hereto):

17 in accordance with the provisions of and rules promulgated under Section 21F of the Securities Exchange Act of 1934 or Section 806 of the Xxxxxxxx-Xxxxx Act of 2002, or any other whistleblower protection provisions of state or federal law or regulation (including the right to receive an award for information provided to any such government agencies). Furthermore, in accordance with 18 U.S.C. § 1833, notwithstanding anything to the contrary in this Agreement: (a) the Executive shall not be in breach of this Agreement, and shall not be held criminally or civilly liable under any federal or state trade secret law (i) for the disclosure of a trade secret that is made in confidence to a federal, state, or local government official or to an attorney solely for the purpose of reporting or investigating a suspected violation of law, or (ii) for the disclosure of a trade secret that is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal; and (b) if the Executive files a lawsuit for retaliation by the Company for reporting a suspected violation of law, the Executive may disclose the trade secret to the Executive’s attorney, and may use the trade secret information in the court proceeding, if the Executive files any document containing the trade secret under seal, and does not disclose the trade secret, except pursuant to court order. [Signature pages follow]

US-DOCS\131055246.15 IN WITNESS WHEREOF, the parties hereto have executed this Agreement on the date and year first above written. GOHEALTH GOHEALTH, INC. By: /s/ Xxxxx Xxxxxx Name: Xxxxx Xxxxxx Title: Chief Legal Officer & Corporate Secretary PARTNERSHIP GOHEALTH HOLDINGS, LLC By: /s/ Xxxxx Xxxxxx Name: Xxxxx Xxxxxx Title: Chief Legal Officer & Corporate Secretary

Signature Page to the Employment Agreement for Xxxxx Xxxxx EXECUTIVE By: /s/ Xxxxx Xxxxx Xxxxx Xxxxx Residence Address: ###

Signature Page to the Employment Agreement for Xxxxx Xxxxx EXHIBIT A RESTRICTIVE COVENANTS AGREEMENT THIS RESTRICTIVE COVENANTS AGREEMENT (“Agreement”), dated as of May 25, 2022, is made between GoHealth, Inc. (“GoHealth”), GoHealth Holdings, LLC, a Delaware limited liability company (the “Partnership” and, together with GoHealth and any subsidiaries, parent companies or affiliates of GoHealth or the Partnership, the “Company”), and Xxxxx Xxxxx (the “Executive”), a resident of the State of Illinois. RECITALS A. The Company and the Executive have entered into that certain Employment Agreement dated the date hereof (the “Employment Agreement”). B. The Executive possesses extensive knowledge and experience regarding the business of the Company and shall benefit from the Employment Agreement. AGREEMENT NOW, THEREFORE, for good and valuable consideration, which includes the Company’s agreement to employ or continue to employ the Executive under the Employment Agreement and all payments and benefits available to the Executive under the Employment Agreement, and in specific consideration for the Company’s agreement to provide the bonus payments set forth in the Employment Agreement, which the Executive acknowledges and agrees is valid and sufficient consideration for the following covenants in this Agreement, the parties hereto agree as follows: 1. Confidential Information; Non-Disclosure. a. Non-Use and Non-Disclosure of Confidential Information. The Executive acknowledges that the Executive currently holds and has access to proprietary and confidential information of the Company and its subsidiaries. The Executive hereby covenants and agrees that neither the Executive nor any of the Executive’s Affiliates (as hereinafter defined) will, at any time, divulge, furnish or make accessible to anyone or use in any way other than in the ordinary course of the business of the Company or its subsidiaries, any confidential, proprietary or secret knowledge or information of the Company that the Executive has acquired or shall acquire about the Company or its subsidiaries, whether developed by the Executive or by others, including, without limitation, knowledge or information concerning (i) any trade secrets, (ii) any confidential, proprietary or secret designs, programs, processes, formulae, plans, devices or material (whether or not patented or patentable) directly or indirectly useful in any aspect of the business of the Company or its subsidiaries, (iii)

14. Headings. The headings contained in this Agreement are for reference purposes only and shall not be deemed to be a part of this Agreement or to affect the meaning or interpretation of this Agreement. 15. Notices. All notices, requests, demands and other communications provided for in this Agreement shall be in writing delivered personally or sent by registered or certified mail, postage prepaid, as follows: If to the Company: GoHealth Holdings, LLC 000 Xxxx Xxxxx Xxxxxx Xxxxxxx, XX 00000 with a copy to: Centerbridge Partners, L.P. 000 Xxxx Xxx., 00xx Xxxxx Xxx Xxxx, XX 00000 If to the Executive: To the address set forth on the Executive’s signature page of the Employment Agreement 16. Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware, without giving effect to any choice or conflict of law provision or rule, whether of the State of Delaware or any other jurisdiction, that would cause the application of laws of any jurisdiction other than the State of Delaware. 17. Action of Affiliates. The Executive shall cause his Affiliates not to take any action that is prohibited to be taken by such Affiliates under the terms of this Agreement. **[Signature Pages Follow]**

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed as of the date first above written. GOHEALTH, INC. By: /s/ Xxxxx Xxxxxx Name: Xxxxx Xxxxxx Its: Chief Legal Officer & Corporate Secretary GOHEALTH HOLDINGS, LLC By: /s/ Xxxxx Xxxxxx Name: Xxxxx Xxxxxx Its: Chief Legal Officer & Corporate Secretary EXECUTIVE /s/ Xxxxx Xxxxx Xxxxx Xxxxx
